RESEARCH ARTICLE

Ophthalmic features of HIV associated cryptococcal meningitis in Malawian Adults: an observational study [version 1; peer review: 2 approved with reservations]

Jayne P. Ellis1,3, Kate Gaskell1,4, Mary Peirse1, Jack Gormley1,5, Newton Kalata1,6, Philip I. Burgess5, Patty Mopamboli6, Chatonda A. Manda6, Christine A. Kiire1,7, Ian Maccormick1,5, Ebbie Gondwe1, Sile Molloy8, Thomas S. Harrison8, David G. Lalloo9, Robert S. Heyderman1,3

1Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi
2University College London Hospitals NHS Trust, London, UK
3Division of Infection and Immunity, University College London, London, UK
4London School of Hygiene & Tropical Medicine, London, UK
5Department of Eye and Vision Science, University of Liverpool, Liverpool, UK
6University of Malawi College of Medicine, Blantyre, Malawi
7Oxford Eye Hospital, John Radcliffe Hospital, Oxford, UK
8Institute for Infection and Immunity, St George's, University of London, London, UK
9Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK

Abstract

Background: Cryptococcal meningitis (CM) is the commonest neurological complication in patients with advanced HIV. Visual disturbance is a frequent presenting symptom. Papilloedema is commonly reported but other ophthalmic findings are not well described.

Methods: We performed an observational study comparing severely immunocompromised HIV-infected patients with and without CM to determine the nature and prevalence of retinal pathology attributable to CM. 70 adult patients were enrolled in Blantyre Malawi, 35 with CM and 35 HIV-infected patients without CM.

Results: 79% (19/24) of CM patients examined on day one had evidence of retinal abnormalities compared to 17% (6/35) of HIV-infected controls (p <0.001). In the CM group, retinal whitening was the commonest abnormality (50%), followed by optic disc swelling (29%), haemorrhage (25%) and vascular abnormalities (7%). Retinal whitening was the only abnormality observed in the comparator group (17%). In CM, there was no significant difference between those with and without retinal abnormalities in fungal burden (13,550 cfu/ml vs. 9,150 cfu/ml; p = 0.65), CD4 count (28 cells/µl vs. 76 cells/µl; p = 0.79) or CSF opening pressure (21cm H20 vs. 27cm H20; p = 0.5). There was no association between presence/absence of retinal abnormalities and death (40% 10-week mortality vs. 26%; p = 0.6).

Conclusions: Whether the presence of CM retinopathy could be used as a
Any reports and responses or comments on the article can be found at the end of the article.

Keywords
HIV, cryptococcal meningitis, retinopathy, ophthalmic signs, Africa

This article is included in the Malawi-Liverpool Wellcome Trust Clinical Research Programme gateway.

Corresponding author: Jayne P. Ellis (j.ellis@doctors.org.uk)

Author roles: Ellis JP: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing; Gaskell K: Conceptualization, Data Curation, Investigation, Methodology, Project Administration, Writing – Review & Editing; Peirse M: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Writing – Review & Editing; Gormley J: Data Curation, Formal Analysis, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing; Kalata N: Conceptualization, Data Curation, Investigation, Methodology, Project Administration, Writing – Review & Editing; Burgess PI: Conceptualization, Data Curation, Investigation, Writing – Review & Editing; Mopamboli P: Data Curation, Investigation, Writing – Review & Editing; Manda CA: Data Curation, Investigation; Kiire CA: Data Curation, Investigation, Writing – Review & Editing; Maccormick I: Conceptualization, Data Curation, Investigation, Methodology, Writing – Review & Editing; Gondwe E: Data Curation, Project Administration; Molloy S: Formal Analysis, Writing – Review & Editing; Harrison TS: Conceptualization, Funding Acquisition, Resources, Supervision, Writing – Review & Editing; Laloo DG: Conceptualization, Funding Acquisition, Resources, Supervision, Writing – Review & Editing; Heyderman RS: Conceptualization, Funding Acquisition, Methodology, Resources, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by the Wellcome Trust through a strategic award to the Malawi-Liverpool-Wellcome Trust Clinical Research Programme [101113] The Advancing Cryptococcal meningitis Treatment for Africa (ACTA) trial was funded by the Medical Research Council UK [100504], and Agence Nationale de Recherches sur le Sida et les Hépatites Virales [ANRS12275]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2019 Ellis JP et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Ellis JP, Gaskell K, Peirse M et al. Ophthalmic features of HIV associated cryptococcal meningitis in Malawian Adults: an observational study [version 1; peer review: 2 approved with reservations] Wellcome Open Research 2019, 4:83 (https://doi.org/10.12688/wellcomeopenres.15067.1)

First published: 20 May 2019, 4:83 (https://doi.org/10.12688/wellcomeopenres.15067.1)
Background
Cryptococcal meningitis (CM) remains a leading cause of death in patients with advanced HIV, accounting for 15% of AIDS-related deaths in 2014. Visual disturbances associated with cryptococcal meningitis are common including reduced visual acuity, blurred vision, diplopia and photophobia. In a South African study of patients with HIV-associated CM due to Cryptococcus neoformans, 46.5% (40/86) had decreased visual acuity. Visual loss was also reported frequently in CM caused by Cryptococcus gattii, in 82 immunocompetent patients from Papua New Guinea, visual loss occurred in 52.6% of survivors. Visual loss may occur secondary to raised intracranial pressure or be due to direct fungal invasion of the optic nerve, optic chiasm or optic tracts. Retinal features associated with CM have not been well-described.

Intracranial hypertension occurs in up to 75% of patients with CM and papilloedema is reported to be the commonest retinal finding, ranging between 33% and 48% of patients. In a study of CM patients with catastrophic visual loss, papilloedema was observed in 70% (33/47). Other ophthalmic features reported to be associated with CM in case reports include: retinal haemorrhages, neuretinitis, multi-focal choroiditis, optic atrophy, vascular tortuosity, exudative retinal detachment, cloudy vitreous, and endophthalmitis. To what extent these changes were attributable to CM rather than HIV retinopathy, or other opportunistic infections e.g. CMV retinitis, is uncertain.

We performed an observational study comparing severely immunocompromised HIV-infected Malawian adults with and without CM to determine the nature and prevalence of retinal pathology attributable to CM. This study was nested within the Advancing Cryptococcal meningitis Treatment for Africa (ACTA) trial.

Methods
The ACTA trial was a Phase III multi-centre randomised controlled trial which aimed to identify the optimal treatment of HIV-associated CM in resource limited settings (ISRCTN45035509). HIV-infected adults with CM were randomised to one of five anti-fungal treatment arms and followed up for 10 weeks. The Queen Elizabeth Central Hospital (QECH), Blantyre, Malawi, was the largest recruiting centre. Patients were treated with antiretroviral therapy (ART) according to national guidelines.

QECH is a large tertiary referral hospital in Southern Malawi. Between March 2014 and July 2015, a subset of consecutively consenting adults from the ACTA trial were recruited into the ophthalmology sub-study. This subset comprised all ACTA patients who were sufficiently stable to comply with a full ophthalmology assessment and able to consent.

Baseline clinical and laboratory data was collected including: duration of ART, CD4 count using case report forms (CRFs); cerebrospinal fluid (CSF) opening pressure was measured using manometers used during lumbar puncture and quantitative cryptococcal culture (QCC) was performed as described previously. Dilated indirect ophthalmoscopy using a hand-held ophthalmoscope was performed by a trained ophthalmologist. Visual acuity was tested using the logMAR (logarithm of the minimum angle of resolution) scale. Low vision was defined as a visual acuity less than +0.50 logMAR but equal to or better than +1.3 logMAR. The team aimed to re-examine participants at day 7, week 4 and week 10. Additional examinations however depended upon participant consent, clinical status and availability of an ophthalmologist.

From November 2015 to June 2016, 35 HIV-infected otherwise healthy patients with CD4 <100 cells/µl were recruited by convenience sampling from QECH antiretroviral clinic as a comparator group. Exclusion criteria were: previous episode of CM or current symptoms or signs of meningitis. Baseline clinical data were collected including: CD4 count, ART use and co-morbidities using standardised CRFs. Visual acuity testing using the logMAR scale and dilated indirect ophthalmoscopy using a hand-held ophthalmoscope, was performed at recruitment only.

Ethics: The ACTA trial protocol was approved by the London School of Hygiene and Tropical Medicine Research Ethics Committee (REC) (8854 – 5) and the University of Malawi, College of Medicine Research Ethics Committee (COMREC) (P.11/11/1149). The sub-study protocol was approved by COMREC (P.11/11/1149). Written informed consent was obtained from all participants.

Statistical analysis: Descriptive summaries were used to analyse the observational data as proportions or medians with ranges. We used SAS (version 9.3) to calculate Fisher’s exact or the Mann Whitney tests to compare groups. For the descriptive analysis, ophthalmic abnormalities were divided into 4 groups: (i) retinal whitening which included retinal discoulouration, cotton wool spots, white plaques and choroidal lesions (ii) optic disc swelling (iii) haemorrhage and (iv) vascular abnormalities including vascular tortuosity and dilated vessels.

Results
46 CM patients recruited to the ACTA study were screened for recruitment to the ophthalmology sub-study. Eight patients died before an ophthalmological examination could be performed, one patient was deemed too unwell, one patient was subsequently excluded from the ACTA trial and one patient was lost to follow up. 35 HIV-infected patients without CM were also recruited (see underlying data).

Baseline characteristics
The median age was 35 years in both groups (range 29 – 51 in CM group, 22-62 in HIV-infected comparator group), 71% (25/35) were male in the CM group compared with 51% (18/35) in the HIV-infected comparator group (p = 0.06). All participants had advanced HIV and there was no difference in the median CD4 counts between groups: 28 cells/µl in the CM group vs. 44 cells/µl in the HIV-infected comparator group (p = 0.21). There was no difference in the proportion of patients on ART between groups (16/35, 46% and 14/35, 43%, p = 0.63). 11% (4/35) of CM patients reported visual loss at recruitment, but on formal logMAR testing 39% (7/18) had evidence of reduced visual acuity, 2/18 (11%) were blind. Patients with CM were
more likely to have reduced visual acuity compared to the HIV-infected comparator group (39% vs. 9%, p = 0.02).

**Ophthalmic signs**

79% (19/24) of CM patients examined on day one had evidence of retinal abnormalities compared to 17% (6/35) of the HIV-infected controls (p <0.001) (Table 1).

82% (23/28) of CM patients examined within one week of CM diagnosis had evidence of retinopathy. In this first week, retinal whitening was the commonest abnormality observed (14/28, 50%), followed by optic disc swelling (8/28, 29%), haemorrhage (7/28, 25%), vascular abnormalities (2/28, 7%) and cloudy vitreous (2/28, 7%) (Table 1, Figure 1). 75% (6/8) of patients with optic disc swelling had raised intracranial pressure (CSF opening pressure > 20cm H20) and 35% (6/17) of patients with raised intracranial pressure had optic disc swelling. To investigate the relationship between retinopathy and CM disease severity, an association between the following indicators and the presence or absence of retinopathy (observed ≤ one week after CM diagnosis) was explored. There was no significant difference in fungal burden (median QCC: 13,550 cfu/ml vs.

### Table 1. Prevalence of retinal pathology in Cryptococcal Meningitis (CM) patients.

<table>
<thead>
<tr>
<th>Time of fundoscopy</th>
<th>Abnormal fundoscopy N (%)</th>
<th>Retinal whitening N (%)</th>
<th>Optic disc swelling N (%)</th>
<th>Retinal haemorrhage N (%)</th>
<th>Vascular abnormality N (%)</th>
<th>Other* N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CM Week 1</td>
<td>23/28 (82)</td>
<td>14/28 (50)</td>
<td>8/28 (29)</td>
<td>7/28 (25)</td>
<td>2/28 (7)</td>
<td>2/28 (7)</td>
</tr>
<tr>
<td>CM Week 4 – 10</td>
<td>8/13 (61)</td>
<td>6/13 (46)</td>
<td>1/13 (8)</td>
<td>1/13 (8)</td>
<td>1/13 (8)</td>
<td>0/7 (0)</td>
</tr>
<tr>
<td>HIV-infected controls</td>
<td>6/35 (17)</td>
<td>6/35 (17)</td>
<td>0/35 (0)</td>
<td>0/35 (0)</td>
<td>0/35 (0)</td>
<td>0/35 (0)</td>
</tr>
</tbody>
</table>

*Other* = cloudy vitreous.

![Figure 1](image-url) **Figure 1**: Retinal photographs taken from patients with HIV associated cryptococcal meningitis. **1a** shows localised vascular tortuosity (blue arrow) with associated haemorrhage (green arrow). **1b** shows a cotton wool spot (blue arrow). **1c** shows swelling of the nasal optic disc margin (blue arrow). **1d** shows vascular engorgement and focal tortuosity (blue arrows). **1e** shows atypical retinal whitening (blue arrow) and nasal disc swelling (green arrow). **1f** shows a white centred haemorrhage (blue arrow).
The highest prevalence (82%) of retinopathy in CM was observed during the first week after diagnosis. In a subset of patients examined between week 4–10, fewer (61%) had evidence of retinopathy. The resolution of the ophthalmic features associated with CM has not been reported previously4–8,13 and therefore needs to be investigated in larger cohorts.

Although patients with evidence of CM retinopathy had lower median CD4 counts and higher fungal burdens, our study was underpowered to detect a clear association with these features or indeed death. In a study of 80 HIV-associated CM cases from Rwanda, there was a non-significant trend towards shorter median survival times in patients with cotton wool spots (102 days) compared to those without cotton wool spots (186 days)7. Future larger studies of CM should determine whether the retinal abnormalities associated with CM could be used as a marker of disease severity.

The strength of this study was that it was nested within a randomized controlled trial which provided standardized data collection, diagnosis and treatment. All patients were examined by a trained ophthalmologist and in contrast to other case series, we had a severely immunocompromised HIV-infected comparator group. This study was limited by the relatively small number of participants, many of whom were only examined at a single time point. Although the cohort characteristics were similar to the main ACTA trial10, we have inevitably sampled patients with less severe CM, who were able to tolerate and consent to an ophthalmological assessment.

### Conclusion

Optic disc swelling, retinal haemorrhages and vascular abnormalities are commonly observed in patients with acute CM, with the highest prevalence in the first week following diagnosis. Whether the presence of CM retinopathy could be used as a marker of CM severity warrants further investigation. The observed ophthalmic findings provide a descriptive framework for CM retinopathy to be utilised in future CM studies.

### Data availability

Figsare: Ophthalmic features and clinical data of HIV-infected Malawian adults with and without cryptococcal meningitis. https://doi.org/10.6084/m9.figshare.8082275

This project contains the following underlying data:

- RDS-SPRN-00282 resubmission.xlsx (Spreadsheet containing demographic, clinical, lab and ophthal data for all participants)

Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).

### Grant information

This work was supported by the Wellcome Trust through a strategic award to the Malawi-Liverpool-Wellcome Trust Clinical Research Programme [101113]
The Advancing Cryptococcal meningitis Treatment for Africa (ACTA) trial was funded by the Medical Research Council UK [100504], and Agence Nationale de Recherches sur le Sida et les Hépatites Virales [ANRS12275].

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements
We would like to acknowledge Professor Simon Harding (Department of Eye and Vision Science, University of Liverpool) for the ophthalmological mentorship and support he offered during the course of this study. We thank all the participants and their families, and gratefully acknowledge the support offered by the staff at all trial sites.

References

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text


PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

Wellcome Open Research 2019, 4:83 Last updated: 03 APR 2020
Open Peer Review

Current Peer Review Status: ?  ?

Version 1

Reviewer Report 07 August 2019

https://doi.org/10.21956/wellcomeopenres.16437.r35940

© 2019 Williamson P et al. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peter R. Williamson
Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Baltimore, MD, USA

Seher Anjum
Laboratory of Clinical Immunology and Microbiology, National Institute of Health (NIH), Bethesda, MD, USA

This is an observational study performed in Malawi comparing retinal findings in HIV patients (with CD4 counts <100) with and without cryptococcal meningitis. The HIV associated CM patient cohort (n=35) is derived from the ACTA study, which was a multi-center RCT done to compare oral and parenteral antifungal therapies to treat CM in resource-limited settings.

• While one of the major aims of this study is contrast between findings attributable to CM versus HIV retinopathy alone, there is no mention of other ocular opportunistic infections being ruled out in those with retinal findings.

• This study may not accurately represent the prevalence/severity of retinal findings in this population since patients who were unstable and couldn’t consent to a complete ophthalmological exam were not included.

• This study would be more informative if the retinal findings could be correlated or defined in terms of the severity of vision loss. For instance, retinal whitening was the most common abnormality found in HIV positive CM patients and persisted in a couple of patients despite antifungals – what degree of visual loss did they have and what does this mean functionally for the patient? It may be better to explain logMAR testing a little more.

• It is unclear at what time point HIV-positive non-CM patients were being examined. How many months on average had they been on ART when they were examined for the first time?

Overall, this is a good descriptive study for retinal findings in HIV positive CM patients. Most cases reported in the literature previously are case reports. However, it is underpowered to study final visual outcomes and to correlate retinal findings with an elevated ICP or morbidity. These caveats should be included under limitations of the study.
Is the work clearly and accurately presented and does it cite the current literature? Yes

Is the study design appropriate and is the work technically sound? Yes

Are sufficient details of methods and analysis provided to allow replication by others? Partly

If applicable, is the statistical analysis and its interpretation appropriate? I cannot comment. A qualified statistician is required.

Are all the source data underlying the results available to ensure full reproducibility? Yes

Are the conclusions drawn adequately supported by the results? Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Translational mycology (specifically work with Cryptococcus).

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.

Reviewer Report 24 June 2019
https://doi.org/10.21956/wellcomeopenres.16437.r35672

© 2019 Pérez H et al. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Héctor Pérez**
Infectious Diseases Division, Fernández Hospital, Buenos Aires, Argentina

**Claudia Frola**
Hospital “Juan A. Fernandez”, Buenos Aires, Argentina

**Background**
- How the retinal pathology attributable to cryptococcus was defined.

**Methods**
- When the duration of antiviral treatment and the count of lymphocyte sub-populations were considered, it would take into account the time of HIV infection, since the same infection can cause retinopathy associated with it.
When referring healthy patients with severe immunosuppression <100 CD4, are they considered not having another opportunistic infection, since it only refers to not having cryptococcosis.

**Results**

- The analysis of the results is not clear. Of the thirty-five patients, 28 were analyzed. It is also not clear those who had visual acuity decrease, refers to having made logMAR to eighteen.

- In the table that analyzes the results, it is unclear that thirteen of thirty-five were evaluated between four to ten weeks after diagnosis and the beginning of the antifungal therapy, therefore the findings of retinopathy are inconsistent.

**Conclusions**

- Finally, the findings of retinopathy, co-calculated with the results described, is difficult to consider as a marker of severity in CM, because patients who were more severe were excluded, that is, there could be other associated injuries.

**Is the work clearly and accurately presented and does it cite the current literature?**

Partly

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Partly

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

Partly

**Are the conclusions drawn adequately supported by the results?**

Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Infectious Diseases Physicians.

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.